Interdisciplinary oncology conference conclusion
LISOD
Israel Oncology Hospital
08720, Kyiv region, Obukhiv district,
village Plyut, str. Malyshka, 27
phone +38044 520 94 00
fax +38044 520 94 01
www.lisod.ua
CONCLUSION
of the interdisciplinary oncology conference
from May 03, 2023
The conference participants:
Dr. Andrii Saulov, MD - head of the oncology conference, clinical oncologist
Prof. Alla Vinnytska, MD, PhD - chief physician
Dr. Maxim Ermakov, MD - clinical oncologist of the consulting department
Dr. Andrii Izhik, MD - clinical oncologist of the consulting department
Dr. Meir Zaavi, MD - clinical oncologist of the consulting department
Dr. Yuliya Butusova, MD - clinical oncologist of the consulting department
Dr. Nataliya Kasyan, MD - head of the chemotherapeutic department
Dr. Mykola Novikov, MD, PhD - candidate of medical sciences, head of the radiation diagnostics department
Dr. Serhii Pryndyuk, MD, PhD - candidate. medical sciences, urologist, clinical oncologist of the consulting department
Dr. Maryna Sokolovska, MD, PhD - candidate. medical sciences, head of the radiology department
Anastasia Stanislavivna Zherlitsina
Apr 25, 1976
ID: 110889
Diagnosis: Leiomyosarcoma of the uterine body, T2NxM1, secondary liver, peritoneum damage.
Condition after 4 cycles of chemotherapy according to the Gemcitabine + Docetaxel + Avastin protocol with progression of the disease in the liver (according to CT, MRI from 10/2022). C-KIT, MET (ONCOMINE) mutation was detected. The condition after treatment with Pazopanib (05-12/01/2023) with the development of the posterior reversible encephalopathy syndrome and positive dynamics according to the CT data.
01/2023 - repeated liver biopsy. Pathohistological conclusion - uterine leiomyosarcoma metastasis. Condition after 3 cycles of chemotherapy according to the Trabectedin protocol with negative X-ray dynamics (PET/CT from 11/04/2023). Suspicion of the presence of synchronous neoplasia of the stomach (GIST?). Condition after EUS-FNA of gastric biopsy, liver core biopsy, histologically - gastrointestinal stromal tumor (GIST) of the stomach, GIST metastasis in the liver (CSD).
Recommended:
Start treatment with Imatinib at a dose of 400 mg per day with condition control (clinical examination + CT scan in comparison) after 3 months of treatment.
Revision of histological preparations from 08/2022 in the reference laboratory (Frankfurt/CSD) for the purpose of differential diagnosis of uterine leiomyosarcoma and GIST.
Evaluating follow-up tactics based on FoundationOne research results.
If you have suggestions or comments about the work of our hospital, please contact us on the "LISOD Hospital Hotline" - 0 800 50 51 58 (toll-free from any phone number within Ukraine).
All recommendations given in this Conclusion are prescribed and should be carried out exclusively under the supervision of a treating physician.